A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Pamrevlumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms ZEPHYRUS; ZEPHYRUS-1
- Sponsors FibroGen
Most Recent Events
- 22 May 2024 Results presented at the 120th International Conference of the American Thoracic Society.
- 08 Dec 2023 Status changed from active, no longer recruiting to discontinued.
- 26 Jun 2023 According to a FibroGen media release, company plans to communicate the results of the ZEPHYRUS-1 study at an upcoming medical forum.